Duration of Dual Antiplatelet Therapy

Slides:

Advertisements

Similar presentations

WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.

Advertisements

Supplementary Appendix Thrombotic Risk Scores % of Patients Risk Categories Low Risk (n=3491) Intermediate Risk (n=2806)

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Disclosures Speaker’s bureau: Research support: Consulting: Equity

Stent Thrombosis and Optimal Duration of DAPT

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

Short versus Long DAPT Studies – An Academic View

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

European and US Guidelines

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Emerging Data on ACS Management From ACC

Applying New Data in Practice:

PAD Patients vs Post-ACS Patients:

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Table. Clinical Efficacy and Safety

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

What Do We Know About LDL-C?

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

Tailoring Antiplatelet Therapy in PCI

Recurrent Angina: New Tools for an Old Problem

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

CV Risk Doesn't End in the Cath Lab

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Mortality Data From the BASKET LATE Trial and PREMIER Registry

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

Updates in Anticoagulation: Key Sessions at ESC 2017

What oral antiplatelet therapy would you choose?

Elevated Admission Plasma Glucose Following ACS

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Improving Adherence to Antiplatelet Therapy After an ACS Event

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.

Primary safety endpoint

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

ESC Guideline on the Management of STEMI Recommendation for DAPT

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Antithrombotic Therapy in AF Patients Undergoing PCI

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

Duration of Dual Antiplatelet Therapy

European and US Guidelines

PCI-CURE CV Death or MI

CHARISMA Instantaneous Hazard for Moderate or Severe Bleeding

CHARISMA Primary End Point

TRILOGY-ACS Primary Efficacy End Point to 30 Months (Age < 75 years)

DAPT Trial Total Enrollment

DES vs BMS

DAPT Trials Unanswered Questions

OPTIMIZE Second-generation DES Effect of Short- and Long-term DAPT

New Trials With Ticagrelor

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)